The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

This virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of IgG against SARS-CoV-2 in approximately 800 patients as measured by Dried Blood Spots via fingerstick using the Everlywell COVID-19 Antibody Test Home Collection Kit. Participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.

Inclusion Criteria:

• Age ≥ 18 years
• Willing to provide informed consent prior to participation.
• Cohort 1 (Arm 1) - Positive test results for SARS-CoV-2 virus by an RT-PCR or Antigen test AND not received any COVID-19 vaccine or participated in any COVID-19 vaccine trial
• Cohort 2 (Arm 2) - Received the COVID-19 vaccine

Exclusion Criteria:

• Unable or unwilling to provide informed consent
• Individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy

Participants who have tested positive for SARS-CoV-2 by either RT-PCR or Antigen test for COVID-19 or have received one of the commercially available SARS-CoV-2 vaccines.